DiaMedica Therapeutics Inc. (DMAC)

US — Healthcare Sector
Peers: MIST  MCRB  IKT  ONCY  SCPH  LIFE  LYRA  CNTA  IOVA    XFOR  GRTX  TERN  DAWN  HOOK 

Automate Your Wheel Strategy on DMAC

With Tiblio's Option Bot, you can configure your own wheel strategy including DMAC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DMAC
  • Rev/Share 0.0
  • Book/Share 0.7925
  • PB 5.1861
  • Debt/Equity 0.0093
  • CurrentRatio 8.0219
  • ROIC -0.8496

 

  • MktCap 176251185.0
  • FreeCF/Share -0.5275
  • PFCF -7.7987
  • PE -6.5218
  • Debt/Assets 0.0081
  • DivYield 0
  • ROE -0.6135

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 2
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation DMAC H.C. Wainwright -- Buy -- $7 Oct. 7, 2024

News

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
DMAC
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Ton.

Read More
image for news DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DMAC
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call.

Read More
image for news DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
DMAC
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Oppenheimer representative to a.

Read More
image for news DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

About DiaMedica Therapeutics Inc. (DMAC)

  • IPO Date 2012-08-03
  • Website https://www.diamedica.com
  • Industry Biotechnology
  • CEO Mr. Dietrich John Pauls MBA
  • Employees 27

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.